Methods and means for typing a sample comprising colorectal cancer cells

1. A method for typing a RNA sample of an individual suffering from colorectal cancer or suspected of suffering therefrom, the method comprising

a. providing an RNA sample that is prepared from a tissue sample from said individual, said tissue sample comprising colorectal cancer cells or suspected to comprise colorectal cancer cells;

b. determining RNA levels for a set of genes in said RNA sample by microarray analysis; and

c. typing said RNA sample on the basis of the RNA levels determined for said set of genes;

wherein said set of genes comprises at least MCTP1 comprising SEQ ID NO: 36 and THNSL2 comprising SEQ ID NO: 13.

2. The method of claim 1 , wherein said set of genes further comprises LAMA3 comprising SEQ ID NO: 33, CTSC comprising SEQ ID NO: 9, PYROXD1 comprising SEQ ID NO: 5, EDEM1 comprising SEQ ID NO: 10, IL2RB comprising SEQ ID NO: 39, ZNF697 comprising SEQ ID NO: 30, SLC6A12 comprising SEQ ID NO; 12 and IL2RA comprising SEQ ID NO: 7.

3. The method of claim 1 , whereby said set of genes further comprises, LAMA3 comprising SEQ ID NO: 33, CTSC comprising SEQ ID NO: 79, PYROXD1 comprising SEQ ID NO: 181, EDEM1 comprising SEQ ID NO: 10, IL2RB comprising SEQ ID NO: 39, ZNF697 comprising SEQ ID NO: 30, SLC6A12 comprising SEQ ID NO: 12, IL2RA comprising SEQ ID NO: 7, CYFIP2 comprising SEQ ID NO: 38, PIM3 comprising SEQ ID NO: 22, LIF comprising SEQ ID NO: 2, M6PRBP1 comprising SEQ ID NO: 11, CA438802 comprising SEQ ID NO: 35, HSD3B1 comprising SEQ ID NO: 37, ZBED4 comprising SEQ ID NO: 1, and PPARA comprising (SEQ ID NO: 23).

4. The method according to claim 1 , further comprising normalizing the determined RNA levels of said set of genes in said sample.

5. The method according to claim 1 , whereby said colorectal cancer comprises a TNM stage I, TNM stage II or TNM stage III cancer according to the TNM Staging System.

6. The method according to claim 1 , whereby said typing differentiates cancer cells with a low metastasizing potential and cancer cells with a high metastatic potential.

7. A method of classifying an individual suffering from colorectal cancer, comprising:

classifying said individual as having a poor prognosis or a good prognosis by a method comprising:

(a) providing an RNA sample from a said individual that is prepared from a tissue sample from said individual, said tissue sample comprising colorectal cancer cells or suspected to comprise colorectal cancer cells;

(b) determining a level of RNA for a set of genes comprising at least MCTP1 comprising SEQ ID NO: 36 and THNSL2 comprising SEQ ID NO: 13 in said sample;

(c) determining a similarity value between a level of expression from the set of genes in said individual and a level of expression from said set of genes in a patient having no recurrent disease within five years of initial diagnosis; and

(d) classifying said individual as having a poor prognosis if said similarity value is below a first similarity threshold value, and classifying said individual as having a good prognosis if said similarity value exceeds said first similarity threshold value.

8. The method of claim 7 , whereby the determined level of RNA for said set of genes is normalized.

9. A method of assigning treatment to a individual suffering from colorectal cancer, comprising

(a) classifying said individual as having a good prognosis or a poor prognosis according to claim 7 ;

(b) assigning chemotherapy if said individual is classified as having said poor prognosis.

10. The method according to claim 1 , whereby said colorectal cancer comprises a colon cancer.

11. The method according to claim 7 , whereby said colorectal cancer comprises a colon cancer.

12. The method according to claim 1 , whereby a ratio of expression of MCTP1 comprising SEQ ID NO: 36 and THNSL2 comprising SEQ ID NO: 13 is determined.